Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Victoria Luchenko"'
Autor:
Richard L. Piekarz, Susan E. Bates, Tito Fojo, William D. Figg, Monica Skarulis, John Wright, David Venzon, Sue Woo, Robin Frye, Deb Draper, James Reynolds, Kambiz Ghafourian, Cody J. Peer, Victoria Luchenko, Laleh Amiri-Kordestani
Supplementary Tables - PDF file 33K, Supplementary Table 1. Dose levels, dose administered on each treatment day, days 1,3, and 5 of a 21-day cycle, and number of patients treated on each dose level. Supplementary Table 2. Romidepsin toxicities found
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ade7b0319a628d926a54a4d23879983
https://doi.org/10.1158/1078-0432.22449377
https://doi.org/10.1158/1078-0432.22449377
Autor:
Richard L. Piekarz, Susan E. Bates, Tito Fojo, William D. Figg, Monica Skarulis, John Wright, David Venzon, Sue Woo, Robin Frye, Deb Draper, James Reynolds, Kambiz Ghafourian, Cody J. Peer, Victoria Luchenko, Laleh Amiri-Kordestani
Supplementary Figure 1 - PDF file 176K, Supplementary Figure 1: Comparison of dose-normalized CMAX (A) and AUCLAST (B) for the present phase I trial versus data obtained on the phase II NCI1312 trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51d5054b4723086189b3e1c13e2962fa
https://doi.org/10.1158/1078-0432.22449380
https://doi.org/10.1158/1078-0432.22449380
Autor:
Richard L. Piekarz, Susan E. Bates, Tito Fojo, William D. Figg, Monica Skarulis, John Wright, David Venzon, Sue Woo, Robin Frye, Deb Draper, James Reynolds, Kambiz Ghafourian, Cody J. Peer, Victoria Luchenko, Laleh Amiri-Kordestani
Purpose: Romidepsin is a potent histone deacetylase inhibitor (HDI) with activity in T-cell lymphoma. Given preclinical data showing greater induction of gene expression with longer exposures to HDIs, a phase I study of a day 1, 3, and 5 romidepsin s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c715b70975086be5f80e586587d5862
https://doi.org/10.1158/1078-0432.c.6521642
https://doi.org/10.1158/1078-0432.c.6521642
Autor:
Robert W. Robey, Arup R. Chakraborty, Joel P. Schneider, Agnes Basseville, Susan E. Bates, Gary T. Pauly, Julian C. Bahr, Hanna Kozlowski, Paresma Patel, Victoria Luchenko, Michael M. Gottesman
Publikováno v:
Oncotarget
// Julian C. Bahr 1, * , Robert W. Robey 1, 2, * , Victoria Luchenko 1 , Agnes Basseville 1 , Arup R. Chakraborty 1 , Hanna Kozlowski 2 , Gary T. Pauly 3 , Paresma Patel 3 , Joel P. Schneider 3 , Michael M. Gottesman 2 , Susan E. Bates 1, 4 1 Develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26ba77e65e9b74db7882543e538cf912
http://europepmc.org/articles/PMC5340114
http://europepmc.org/articles/PMC5340114
Autor:
Laleh Amiri-Kordestani, Deb Draper, Kambiz Ghafourian, Robin Frye, Cody J. Peer, David Venzon, William D. Figg, John J. Wright, Susan E. Bates, Tito Fojo, Richard Piekarz, Victoria Luchenko, James C. Reynolds, Sue Woo, Monica C. Skarulis
Publikováno v:
Clinical Cancer Research. 19:4499-4507
Purpose: Romidepsin is a potent histone deacetylase inhibitor (HDI) with activity in T-cell lymphoma. Given preclinical data showing greater induction of gene expression with longer exposures to HDIs, a phase I study of a day 1, 3, and 5 romidepsin s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2c7088f5d2ee24e51087836e4e52952
https://doi.org/10.1158/1078-0432.ccr-13-0095
https://doi.org/10.1158/1078-0432.ccr-13-0095
Autor:
Victoria Luchenko, Nathan L. Collie, Richard Piekarz, Michael M. Gottesman, Arup R. Chakraborty, Robert W. Robey, Jean-Pierre Gillet, Louise C. Showe, Zhirong Zhan, Andrew V. Kossenkov, Susan E. Bates, Julia Wilkerson
Publikováno v:
Blood. 121:4115-4125
To identify molecular determinants of histone deacetylase inhibitor (HDI) resistance, we selected HuT78 cutaneous T-cell lymphoma (CTCL) cells with romidepsin in the presence of P-glycoprotein inhibitors to prevent transporter upregulation. Resistant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d393edf84f56488d755208c4aac09212
https://doi.org/10.1182/blood-2012-08-449140
https://doi.org/10.1182/blood-2012-08-449140
Autor:
Yves Pommier, Robert F. Murphy, Crystal D. Salcido, Giuseppe Giaccone, Yong-Wei Zhang, Edina Komlodi-Pasztor, Susan E. Bates, Keli Agama, Victoria Luchenko, Lyuba Varticovski
Publikováno v:
Cell Cycle. 10:3119-3128
Small cell lung cancer (SCLC) is an aggressive lung cancer subtype in need of better therapies. Histone deacetylase inhibitors (HDIs) promote increased lysine acetylation in nucleosomal histones and are thought to relax chromatin, thereby allowing in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62de132d57ac68465356f79c47501001
https://doi.org/10.4161/cc.10.18.17190
https://doi.org/10.4161/cc.10.18.17190
Autor:
Susan E. Bates, David Levens, Wilfred D. Stein, Arup R. Chakraborty, Julia Wilkerson, Christopher B. Devor, Robert W. Robey, Lois Bangiolo, Thomas Litman, Victoria Luchenko, Aaron Heffner
Publikováno v:
Molecular oncology. 8(8)
Romidepsin and vorinostat are histone deacetylase inhibitors (HDACis) that have activity in T-cell lymphomas, but have not gained traction in solid tumors. To gain deeper insight into mechanisms of HDACi efficacy, we systematically surveyed 19 cell l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f6104184345d7fabdddc61ad89cbcdc
https://pubmed.ncbi.nlm.nih.gov/24954856
https://pubmed.ncbi.nlm.nih.gov/24954856
Autor:
Victoria Luchenko, Seth M. Steinberg, Robert K. Oldham, Deborah Draper, Tito Fojo, Clara C. Chen, A. Robin Frye, Daryl Barnett, Zinnah Caluag, Susan E. Bates, Robert W. Robey, Ronan J. Kelly
Publikováno v:
The oncologist. 17(4)
This pharmacodynamic trial evaluated the effect of CBT-1® on efflux by the ATP binding cassette (ABC) multidrug transporter P-glycoprotein (Pgp/MDR1/ABCB1) in normal human cells and tissues. CBT-1® is an orally administered bisbenzylisoquinoline Pg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59b96f12e58620d1593b207fa35c5538
https://pubmed.ncbi.nlm.nih.gov/22416063
https://pubmed.ncbi.nlm.nih.gov/22416063
Autor:
Agnes Basseville, Robert W. Robey, Arup R. Chakraborty, Zhirong Zhan, Julian C. Bahr, Susan E. Bates, Victoria Luchenko
The histone deacetylase inhibitors (HDIs) have shown promise in the treatment of a number of hematologic malignancies, leading to the approval of vorinostat and romidepsin for the treatment of cutaneous T-cell lymphoma and romidepsin for the treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e728c09ffbe32565707dd0bf430e6a5
https://europepmc.org/articles/PMC3230675/
https://europepmc.org/articles/PMC3230675/